Education
About Us
Working with TipRanks
Follow Us
Monopar Therapeutics Inc (MNPR)
:MNPR
Total Valuation
Monopar Therapeutics Inc has a market cap or net worth of $206.76M. The enterprise value is $197.25M.
Market Cap$206.76M
Enterprise Value$197.25M
Share Statistics
Monopar Therapeutics Inc has 6,169,961 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding6,169,961
Owned by Insiders16.92%
Owned by Institutions20.42%
Financial Efficiency
Monopar Therapeutics Inc’s return on equity (ROE) is -0.28 and return on invested capital (ROIC) is -29.37%.
Return on Equity (ROE)-0.28
Return on Assets (ROA)-0.26
Return on Invested Capital (ROIC)-29.37%
Return on Capital Employed (ROCE)-0.29
Revenue Per Employee0.00
Profits Per Employee-1.11M
Employee Count14
Asset Turnover0.00
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Monopar Therapeutics Inc is ―. Monopar Therapeutics Inc’s PEG ratio is ―.
PE Ratio―
PS Ratio―
PB Ratio―
Price to Fair Value1.51
Price to FCF―
Price to Operating Cash Flow-0.02
PEG Ratio―
Income Statement
In the last 12 months, Monopar Therapeutics Inc had revenue of 0.00 and earned -15.59M in profits. Earnings per share was -4.11.
Revenue0.00
Gross Profit0.00
Operating Income-16.16M
Pretax Income-15.59M
Net Income-15.59M
EBITDA-15.59M
Earnings Per Share (EPS)-4.11
Cash Flow
In the last 12 months, operating cash flow was -11.15B and capital expenditures 0.00, giving a free cash flow of -6.74B billion.
Operating Cash Flow-11.15B
Free Cash Flow-6.74B
Free Cash Flow per Share-1.09K
Dividends & Yields
Monopar Therapeutics Inc pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta2.07
52-Week Price Change1179.07%
50-Day Moving Average37.97
200-Day Moving Average33.64
Relative Strength Index (RSI)39.19
Average Volume (3m)31.07K
Important Dates
Monopar Therapeutics Inc upcoming earnings date is Nov 7, 2025, Before Open (Confirmed).
Last Earnings DateAug 12, 2025
Next Earnings DateNov 7, 2025
Ex-Dividend Date―
Financial Position
Monopar Therapeutics Inc as a current ratio of 11.47, with Debt / Equity ratio of 0.15%
Current Ratio11.47
Quick Ratio11.47
Debt to Market Cap0.00
Net Debt to EBITDA2.94
Interest Coverage Ratio0.00
Taxes
In the past 12 months, Monopar Therapeutics Inc has paid 0.00 in taxes.
Income Tax0.00
Effective Tax Rate0.00
Enterprise Valuation
Monopar Therapeutics Inc EV to EBITDA ratio is -2.41, with an EV/FCF ratio of -5.87.
EV to Sales0.00
EV to EBITDA-2.41
EV to Free Cash Flow-5.87
EV to Operating Cash Flow-5.87
Balance Sheet
Monopar Therapeutics Inc has $39.50B in cash and marketable securities with $80.37M in debt, giving a net cash position of -$39.42B billion.
Cash & Marketable Securities$39.50B
Total Debt$80.37M
Net Cash-$39.42B
Net Cash Per Share-$6.39K
Tangible Book Value Per Share$14.52
Margins
Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.
Gross Margin0.00%
Operating Margin0.00%
Pretax Margin0.00%
Net Profit Margin0.00%
EBITDA Margin0.00%
EBIT Margin0.00%
Analyst Forecast
The average price target for Monopar Therapeutics Inc is $64.25, which is 11.43% higher than the current price. The consensus rating is Strong Buy
Price Target$64.25
Price Target Upside94.70% Upside
Analyst ConsensusStrong Buy
Analyst Count4
Revenue Growth Forecast―
EPS Growth Forecast-66.95%